Clinical uses of pegylated pharmaceuticals in oncology (Q34782116)

4 August 2017

1 reference

title

Clinical uses of pegylated pharmaceuticals in oncology (English)

1 reference

4 August 2017

J Crawford

1

1 reference

4 August 2017

publication date

1 April 2002

1 reference

4 August 2017

published in

Cancer Treatment Reviews

1 reference

4 August 2017

volume

28 Suppl A

1 reference

4 August 2017

page(s)

7-11

1 reference

Pegylation: engineering improved pharmaceuticals for enhanced therapy

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

Novel effects with polyethylene glycol modified pharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980003-2

7 January 2021

10.1016/S0305-7372(02)80003-2

Identifiers

DOI

1 reference

4 August 2017

1 reference